Pharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Targeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Int J Pharm. 2019 Oct 30;570:118645. doi: 10.1016/j.ijpharm.2019.118645. Epub 2019 Aug 26.
Dual-modal imaging probes based on fluorescence (FL) and magnetic resonance (MR) modalities have attracted great attention due to their ability to combine the target specificity and high penetration into body tissues. In this study, we developed a potent nanocarrier with an effective photoluminescent emission and MR imaging capacity to deliver the doxorubicin to breast cancer 4T1 cells. The nanocarrier was fabricated by coating of quantum dots (QDs) with mesoporous silica followed by amine functionalization of the silica surface. Then, the doxorubicin was loaded into the silica pores and biheterofunctional PEG was covalently bound to the surface of core-shell quantum dot mesoporous silica nanoparticles. In order to target the DOX-loaded nanoparticles, the EpCAM DNA aptamer was attached on the surface of the DOX-loaded PEGylated nanoparticles. The synthesized NPs were analyzed for their size distribution, morphology, zeta potential and magnetic susceptibility using HRTEM, SEM and VSM analysis. The QD-encapsulated mesoporous silica revealed spherical shapes with an average particle size of 100 nm. The maximum encapsulation efficacy of doxorubicin in the silica pores was 25%. The in vitro release assessment demonstrated the pH-sensitive release of doxorubicin from the designed formulations. The in vitro cytotoxicity assays indicated that the aptamer targeted nanoparticles showed greater cytotoxicity than both non-targeted NPs and free DOX toward 4T1 and MCF-7 cell lines. The in vivo studies in 4T1 tumor-bearing Balb/c mice demonstrated that EpCAM aptamer could specifically deliver the DOX-loaded nanoparticles into the tumor tissue and cause remarkable inhibition of tumor growth as compared to non-targeted formulation and free DOX. Moreover, the in vivo MR and fluorescent imaging in 4T1 tumor-bearing mice confirmed the accumulation and residence of targeted system in tumor tissue even 24 h post-injection. This work presents a novel system for preparing bimodal imaging theranostic NPs through hybridization of silica and magnetic-fluorescent quantum dots.
基于荧光(FL)和磁共振(MR)模式的双模成像探针由于能够结合靶向特异性和对身体组织的高穿透性而受到极大关注。在这项研究中,我们开发了一种有效的光致发光发射和磁共振成像能力的强效纳米载体,将阿霉素递送到乳腺癌 4T1 细胞。纳米载体是通过量子点(QD)的介孔硅涂层,然后对硅烷表面进行胺功能化来制备的。然后,将阿霉素载入硅烷孔中,并将双功能 PEG 通过共价键合到核壳量子点介孔硅纳米颗粒的表面。为了靶向载药纳米颗粒,将 EpCAM DNA 适体附着在载药 PEG 化纳米颗粒的表面上。通过 HRTEM、SEM 和 VSM 分析对合成的 NPs 进行了粒径分布、形态、Zeta 电位和磁化率分析。QD 包封的介孔硅呈现出球形,平均粒径为 100nm。阿霉素在硅烷孔中的最大包封效率为 25%。体外释放评估表明,设计的制剂具有 pH 敏感性的阿霉素释放。体外细胞毒性测定表明,与非靶向 NPs 和游离 DOX 相比,适体靶向纳米颗粒对 4T1 和 MCF-7 细胞系表现出更高的细胞毒性。在荷 4T1 肿瘤的 Balb/c 小鼠体内研究表明,EpCAM 适体能特异性地将载 DOX 的纳米颗粒递送到肿瘤组织中,并与非靶向制剂和游离 DOX 相比,显著抑制肿瘤生长。此外,荷 4T1 肿瘤小鼠的体内磁共振和荧光成像证实,即使在注射后 24 小时,靶向系统仍能在肿瘤组织中积聚和停留。这项工作提出了一种通过硅和磁性荧光量子点杂交制备双模成像治疗性 NPs 的新系统。